	US 12,240,883 B2
	MAGEA1 specific T cell receptors and their use
Carina Wehner, Munich (DE); Manon Weis, Sankt Wolfgang (DE); Silke Raffegerst, Wald (DE); and Anja Mösch, Munich (DE)
Assigned to Medigene Immunotherapies GmbH, Planegg-Martrinsried (DE)
Appl. No. 17/600,518
Filed by Medigene Immunotherapies GmbH, Planegg-Martinsried (DE)
PCT Filed Apr. 1, 2020, PCT No. PCT/EP2020/059193 § 371(c)(1), (2) Date Sep. 30, 2021, PCT Pub. No. WO2020/201318, PCT Pub. Date Oct. 8, 2020.
Claims priority of application No. 19167440 (EP), filed on Apr. 4, 2019.
Prior Publication US 2023/0037552 A1, Feb. 9, 2023
Int. Cl. C12N 5/02 (2006.01); A61K 39/00 (2006.01); A61P 35/00 (2006.01); C07K 14/47 (2006.01); C07K 14/725 (2006.01); C12N 5/0783 (2010.01); C12N 15/86 (2006.01)

CPC C07K 14/7051 (2013.01) [A61K 39/4611 (2023.05); A61K 39/4632 (2023.05); A61K 39/464486 (2023.05); A61P 35/00 (2018.01); C07K 14/4748 (2013.01); C12N 5/0636 (2013.01); C12N 15/86 (2013.01); C07K 2317/565 (2013.01); C12N 2770/00041 (2013.01)]

9 Claims

1. An isolated T cell receptor (TCR) specific for Melanoma-Associated Antigen 1 (MAGEA1), wherein the TCR comprises

a TCR α chain comprising

a CDR1 having the amino acid sequence of SEQ ID NO: 2,

a CDR2 having the amino acid sequence of SEQ ID NO: 3 and

a CDR3 having the amino acid sequence of SEQ ID NO: 4;

and

a TCR β chain comprising

a CDR1 having the amino acid sequence of SEQ ID NO: 5,

a CDR2 having the amino acid sequence of SEQ ID NO: 6 and

a CDR3 having the amino acid sequence of SEQ ID NO: 7.